| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | esxB |
| Uniprot No | P0C047 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-104aa |
| 氨基酸序列 | MGGYKGIKADGGKVDQAKQLAAKTAKDIEACQKQTQQLAEYIEGSDWEGQFANKVKDVLLIMAKFQEELVQPMADHQKAIDNLSQNLAKYDTLSIKQGLDRVNP |
| 预测分子量 | 19.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是模拟生成的关于esxB重组蛋白的参考文献示例(实际文献请通过学术数据库查询)：
---
1. **文献名称**: *Heterologous Expression and Immunogenicity of ESAT-6-like Protein esxB from Mycobacterium tuberculosis*
**作者**: Smith A, et al.
**摘要**: 本研究在大肠杆菌中成功表达并纯化了重组esxB蛋白，通过动物实验证明其可诱导强烈的Th1型免疫反应，提示其在结核病疫苗开发中的潜在价值。
2. **文献名称**: *Structural and Functional Analysis of the Secreted Protein EsxB in Staphylococcus aureus*
**作者**: Zhang L, et al.
**摘要**: 通过X射线晶体学解析了金黄色葡萄球菌esxB蛋白的三维结构，发现其通过特定的β-链结构介导宿主细胞膜穿孔，为靶向治疗提供了结构基础。
3. **文献名称**: *Recombinant EsxB as a Carrier for Antigen Delivery Enhances Cross-Presentation*
**作者**: Wang Y, et al.
**摘要**: 利用esxB重组蛋白作为抗原载体，证明其可通过MHC-I途径增强抗原交叉呈递，显著提高抗肿瘤疫苗的效力。
4. **文献名称**: *EsxB-mediated Modulation of Host Autophagy in Mycobacterial Infection*
**作者**: Tanaka K, et al.
**摘要**: 研究发现，重组esxB蛋白可干扰宿主细胞自噬通路，促进分枝杆菌在巨噬细胞内的存活，揭示了其免疫逃逸机制。
---
**注意**：以上为模拟内容，具体文献需通过PubMed、Web of Science等平台检索关键词(如"esxB recombinant protein"或"ESAT-6/Esx family")。
**Background of ESxB Recombinant Protein**
ESxB (also known as CFP-10 or EsxH) is a small secretory protein encoded by the *esxB* gene, part of the ESAT-6 (EsxA) secretion system-1 (ESX-1) in *Mycobacterium tuberculosis* and related pathogenic mycobacteria. The ESX-1 system is critical for bacterial virulence, facilitating host cell invasion, immune evasion, and intracellular survival. ESxB, along with its partner protein ESAT-6 (EsxA), forms a tightly bound heterodimer that plays a key role in disrupting host cell membranes, enabling bacterial dissemination and modulation of immune responses.
Recombinant ESxB is produced using genetic engineering techniques, often expressed in *Escherichia coli* or other heterologous systems, followed by purification to homogeneity. This approach allows large-scale production of the protein without handling live pathogenic mycobacteria, enhancing safety and accessibility for research. The recombinant form retains structural and functional properties of native ESxB, including its ability to bind ESAT-6 and interact with host immune components.
Studies on ESxB have focused on its role in tuberculosis (TB) pathogenesis, particularly its involvement in phagosome rupture and escape of *M. tuberculosis* into the host cytosol. Additionally, ESxB is a major antigen recognized by the human immune system, making it a candidate for diagnostic assays (e.g., interferon-gamma release assays) and subunit vaccine development. Its immunodominant epitopes are exploited to differentiate TB-infected individuals from those vaccinated with BCG, which lacks the ESX-1 locus.
Research on recombinant ESxB also extends to understanding host-pathogen interactions, including mechanisms of immune evasion and ESX-1-mediated modulation of autophagy or inflammasome pathways. These insights contribute to therapeutic strategies targeting ESX-1 components to attenuate bacterial virulence or enhance host immunity. Overall, ESxB recombinant protein serves as a vital tool in both basic mycobacteriology and translational applications for TB control.
×
